Canadian Journal of Cardiology

Clinical Significance of Circulating Cardiomyocyte-Specific Cell-Free DNA in Patients With Heart Failure: A Proof-of-Concept Study

Published:October 19, 2019DOI:


      We investigated clinical significance of cell-free DNA (cfDNA) in heart failure. This study enrolled 32 heart failure patients and 28 control subjects. Total cfDNA levels were not different between groups (P = 0.343). Bisulfite-digital polymerase chain reaction using the unmethylated FAM101A locus demonstrated that cardiomyocyte-specific cfDNA was significantly elevated in heart failure patients compared with control subjects (median 0.99 [interquartile range 0.77-1.98] vs 0 [0-0.91] copies/mL; P = 0.003). Cardiomyocyte-specific cfDNA significantly discriminated heart failure patients from control subjects (area under the receiver operating characteristic curve, 0.716; P = 0.003) and was positively correlated with troponin I (r = 0.438; P = 0.003) but not with B-type natriuretic peptide (r = 0.275; P = 0.058). cfDNA may be a novel biomarker to measure cardiomyocyte death in heart failure.


      Nous avons étudié l’importance clinique de l’ADN acellulaire (ADNa) dans l’insuffisance cardiaque chez 32 patients présentant une insuffisance cardiaque et 28 sujets témoins. Les concentrations totales en ADNa ne différaient pas entre les groupes (p = 0,343). L’analyse par réaction de polymérisation en chaîne (PCR) numérique au bisulfite ciblant le locus non méthylé FAM101A a démontré que l’ADNa issu de cardiomyocytes était significativement plus élevé chez les patients présentant une insuffisance cardiaque que chez les sujets témoins (médiane de 0,99 [intervalle écart : 0,77-1,98] vs 0 [0-0,91] copies/ml; p = 0,003). L’ADNa de cardiomyocytes a permis de différencier de manière significative les patients présentant une insuffisance cardiaque des sujets témoins (aire sous la courbe ROC [receiver operating characteristic] : 0,716; p = 0,003) et était corrélé positivement avec le taux de troponine I (r = 0,438; p = 0,003), mais pas avec le taux du peptide natriurétique de type B (r = 0,275; p = 0,058). L’ADNa pourrait servir de nouveau biomarqueur pour mesurer la mort des cardiomyocytes chez les patients présentant une insuffisance cardiaque.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wencker D.
        • Chandra M.
        • Nguyen K.
        • et al.
        A mechanistic role for cardiac myocyte apoptosis in heart failure.
        J Clin Invest. 2003; 111: 1497-1504
        • Missov E.
        • Calzolari C.
        • Pau B.
        Circulating cardiac troponin I in severe congestive heart failure.
        Circulation. 1997; 96: 2953-2958
        • Leon S.A.
        • Shapiro B.
        • Sklaroff D.M.
        • Yaros M.J.
        Free DNA in the serum of cancer patients and the effect of therapy.
        Cancer Res. 1977; 37: 646-650
        • Corcoran R.B.
        • Chabner B.A.
        Application of cell-free DNA analysis to cancer treatment.
        N Engl J Med. 2018; 379: 1754-1765
        • Lehmann-Werman R.
        • Neiman D.
        • Zemmour H.
        • et al.
        Identification of tissue-specific cell death using methylation patterns of circulating DNA.
        Proc Natl Acad Sci U S A. 2016; 113: E1826-E1834
        • Chan K.C.
        • Jiang P.
        • Chan C.W.
        • et al.
        Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.
        Proc Natl Acad Sci U S A. 2013; 110: 18761-18768
        • Yokokawa T.
        • Sugano Y.
        • Shimouchi A.
        • et al.
        Exhaled acetone concentration is related to hemodynamic severity in patients with non-ischemic chronic heart failure.
        Circ J. 2016; 80: 1178-1186
        • Yu J.
        • Miller R.
        • Zhang W.
        • et al.
        Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
        Pharmacogenomics. 2008; 9: 1459-1466
        • Zemmour H.
        • Planer D.
        • Magenheim J.
        • et al.
        Noninvasive detection of human cardiomyocyte death using methylation patterns of circulating DNA.
        Nat Commun. 2018; 9: 1443
        • Misaka T.
        • Yoshihisa A.
        • Yokokawa T.
        • et al.
        Plasma levels of melatonin in dilated cardiomyopathy.
        J Pineal Res. 2019; 66 (e12564)
        • Kostin S.
        • Pool L.
        • Elsasser A.
        • et al.
        Myocytes die by multiple mechanisms in failing human hearts.
        Circulation research. 2003; 92: 715-724
        • Zaravinos A.
        • Tzoras S.
        • Apostolakis S.
        • Lazaridis K.
        • Spandidos D.A.
        Levosimendan reduces plasma cell-free DNA levels in patients with ischemic cardiomyopathy.
        J Thromb Thrombolysis. 2011; 31: 180-187
        • Chang C.P.
        • Chia R.H.
        • Wu T.L.
        • Tsao K.C.
        • Sun C.F.
        • Wu J.T.
        Elevated cell-free serum DNA detected in patients with myocardial infarction.
        Clin Chim Acta. 2003; 327: 95-101
        • Perna E.R.
        • Macin S.M.
        • Canella J.P.
        • et al.
        Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification.
        Circulation. 2004; 110: 2376-2382
        • Pfortmueller C.A.
        • Funk G.C.
        • Marti G.
        • et al.
        Diagnostic performance of high-sensitive troponin T in patients with renal insufficiency.
        Am J Cardiol. 2013; 112: 1968-1972
        • Landesberg G.
        • Jaffe A.S.
        “Paradox” of troponin elevations after noncardiac surgery.
        Br J Anaesth. 2015; 114: 863-865
        • Gauthier V.J.
        • Tyler L.N.
        • Mannik M.
        Blood clearance kinetics and liver uptake of mononucleosomes in mice.
        J Immunol. 1996; 156: 1151-1156
        • Khier S.
        • Lohan L.
        Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature.
        Future Sci OA. 2018; 4: FSO295
        • Gilsbach R.
        • Schwaderer M.
        • Preissl S.
        • et al.
        Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo.
        Nat Commun. 2018; 9: 391

      Linked Article

      • Cardiomyocyte-Specific Cell-Free DNA as a Heart Failure Biomarker?
        Canadian Journal of CardiologyVol. 36Issue 6
        • Preview
          Despite significant advances in the management of heart failure, this disease remains a main cause of mortality and disability. Heart failure affects 1%-2% of the adult population in developed countries and this prevalence rises to more than 10% after 70 years of age.1 Owing to the ageing of the population, the prevalence of heart failure is expected to continue to increase. The health care costs of heart failure also show a continuing rise and represent a significant burden for society.2 Overall, heart failure is a serious public health issue which requires efforts from the research community to develop new drugs and biomarkers to allow movement toward personalized health care.
        • Full-Text
        • PDF